Hospital
Homestead Hospital INC
Homestead Hospital INC was paid $28.41M by Medicaid between Jan 2018 and Dec 2024, across 231 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoHOMESTEAD HOSPITAL INC
HOMESTEAD, FL 33033
HOMESTEAD, FL 33033
33aNPI1578547865assigned 12/01/2005
33bProvider typeRehabilitation Hospital Unit
28Total paid$28.41M
24GClaims1,018,522
24DCodes billed231
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Hospital Unit providers in Florida
Rank by total paid#2 of 11
Median peer was paid$15.92M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 85,352 | $1.86M | |
| 2019 | 227,102 | $3.52M | |
| 2020 | 157,256 | $2.69M | |
| 2021 | 168,808 | $4.56M | |
| 2022 | 186,438 | $6.77M | |
| 2023 | 119,584 | $5.68M | |
| 2024incomplete | 73,982 | $3.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 68,166 | 64,281 | $6.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 58,759 | 54,163 | $5.85M |
| 36415 | Collection of venous blood by venipuncture | 9.8% | 62,914 | 43,154 | $2.79M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 26,842 | 23,311 | $1.91M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.1% | 6,666 | 6,001 | $1.46M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 9,723 | 8,653 | $1.36M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 4,928 | 4,527 | $883K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 9,779 | 9,338 | $831K |
| G0378 | Hospital observation service, per hour | 2.1% | 21,346 | 11,536 | $595K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 16,371 | 13,488 | $454K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.5% | 7,609 | 7,417 | $439K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 2,208 | 1,963 | $384K |
219 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 1,760 | $320K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 14,070 | $288K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,856 | $189K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,998 | $147K |
| 86901 | <1% | 5,019 | $142K | |
| 87088 | <1% | 16,799 | $131K | |
| 87081 | <1% | 5,701 | $130K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,004 | $117K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 871 | $116K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,751 | $107K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,138 | $101K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,880 | $101K |
| 86850 | <1% | 4,950 | $91K | |
| 86900 | <1% | 5,019 | $85K | |
| 82962 | <1% | 8,494 | $84K | |
| 71045 | Radiologic examination, chest; single view | <1% | 22,664 | $79K |
| 81003 | <1% | 10,417 | $71K | |
| 87430 | <1% | 5,879 | $71K | |
| A9270 | Non-covered item or service | <1% | 9,890 | $66K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 55,627 | $66K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,902 | $64K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,330 | $58K |
| 72131 | <1% | 714 | $57K | |
| 71250 | <1% | 1,721 | $54K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 63,472 | $50K |
| 74018 | <1% | 3,295 | $49K | |
| 73630 | <1% | 1,807 | $49K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,846 | $47K |
| 87807 | <1% | 1,260 | $45K | |
| 73610 | <1% | 1,610 | $43K | |
| 80076 | <1% | 30,604 | $43K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,170 | $42K |
| 81001 | <1% | 24,409 | $41K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,867 | $39K |
| 76801 | <1% | 3,403 | $37K | |
| 73562 | <1% | 2,110 | $35K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,758 | $34K |
| 87581 | <1% | 2,132 | $34K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,423 | $34K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,689 | $34K |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 577 | $31K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,267 | $31K |
| 73130 | <1% | 1,259 | $30K | |
| 74021 | <1% | 1,362 | $29K | |
| 12011 | <1% | 594 | $29K | |
| 82947 | <1% | 6,645 | $28K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,868 | $28K |
| 10060 | <1% | 160 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,427 | $25K |
| 87077 | <1% | 3,690 | $24K | |
| 87486 | <1% | 2,843 | $24K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,806 | $24K |
| 84484 | <1% | 15,893 | $24K | |
| 84295 | <1% | 4,441 | $23K | |
| 70486 | <1% | 402 | $23K | |
| 75574 | <1% | 366 | $22K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,382 | $22K |
| 84520 | <1% | 6,102 | $22K | |
| 82565 | <1% | 6,112 | $22K | |
| 85610 | <1% | 16,084 | $22K | |
| 84132 | <1% | 4,467 | $21K | |
| 83735 | <1% | 9,476 | $20K | |
| 73030 | <1% | 1,372 | $20K | |
| 82374 | <1% | 4,261 | $20K | |
| 82435 | <1% | 4,439 | $20K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 162 | $19K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,020 | $19K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 922 | $19K |
| 72100 | <1% | 1,724 | $19K | |
| 12001 | <1% | 431 | $17K | |
| 87040 | <1% | 4,387 | $17K | |
| 85730 | <1% | 14,483 | $15K | |
| 85027 | <1% | 5,428 | $15K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,736 | $15K |
| 73110 | <1% | 824 | $15K | |
| 97161 | <1% | 824 | $14K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,150 | $13K |
| 72040 | <1% | 459 | $13K | |
| 93970 | <1% | 1,034 | $12K | |
| 70491 | <1% | 59 | $12K | |
| 80061 | Lipid panel | <1% | 2,987 | $12K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 309 | $11K |
| 87210 | <1% | 2,219 | $11K | |
| 73080 | <1% | 460 | $10K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,839 | $10K |
| 80051 | <1% | 1,683 | $10K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 156 | $10K |
| 83690 | <1% | 16,960 | $10K | |
| 87205 | <1% | 3,318 | $9K | |
| 96376 | <1% | 5,248 | $9K | |
| 76775 | <1% | 655 | $9K | |
| 73590 | <1% | 370 | $9K | |
| 83880 | <1% | 4,193 | $8K | |
| 82310 | <1% | 1,575 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,939 | $8K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,878 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,148 | $8K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,149 | $8K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,487 | $7K |
| 87186 | <1% | 3,346 | $7K | |
| 73140 | <1% | 171 | $6K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 683 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,391 | $6K |
| 87070 | <1% | 1,572 | $6K | |
| 82550 | <1% | 5,060 | $6K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 36 | $5K |
| 73090 | <1% | 264 | $5K | |
| 85379 | <1% | 3,651 | $5K | |
| 73502 | <1% | 321 | $5K | |
| 82805 | <1% | 1,596 | $5K | |
| 83605 | <1% | 5,030 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,685 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 782 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,571 | $4K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 150 | $4K |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 126 | $4K |
| 87147 | <1% | 888 | $3K | |
| 76536 | <1% | 62 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,766 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 175 | $3K |
| 80053 | Comprehensive metabolic panel | <1% | 3,132 | $3K |
| 96367 | <1% | 955 | $3K | |
| 84145 | <1% | 1,891 | $3K | |
| 82150 | <1% | 2,768 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 275 | $3K |
| 12002 | <1% | 82 | $3K | |
| 95819 | <1% | 116 | $3K | |
| 85652 | <1% | 2,407 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 26 | $2K |
| 93971 | <1% | 301 | $2K | |
| 76641 | <1% | 98 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 92 | $2K |
| 83550 | <1% | 1,082 | $2K | |
| 83540 | <1% | 1,349 | $2K | |
| 82376 | <1% | 1,577 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,743 | $2K |
| 84702 | <1% | 3,970 | $1K | |
| 73552 | <1% | 58 | $959.53 | |
| 82728 | <1% | 1,437 | $927.70 | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $857.39 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,046 | $830.09 |
| 86738 | <1% | 438 | $801.69 | |
| 93975 | <1% | 101 | $799.80 | |
| 83045 | <1% | 1,470 | $790.37 | |
| 93880 | <1% | 119 | $777.00 | |
| 86140 | <1% | 6,032 | $702.58 | |
| 84550 | <1% | 1,462 | $694.05 | |
| 83615 | <1% | 503 | $642.87 | |
| 97162 | <1% | 20 | $630.91 | |
| 81025 | <1% | 323 | $620.71 | |
| 80069 | <1% | 455 | $542.68 | |
| J2704 | Injection, propofol, 10 mg | <1% | 184 | $523.85 |
| 72072 | <1% | 40 | $520.53 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 379 | $517.92 |
| 76770 | <1% | 31 | $443.95 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 147 | $432.58 |
| 86923 | <1% | 149 | $429.21 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 194 | $416.54 |
| 87899 | <1% | 365 | $407.73 | |
| 87046 | <1% | 370 | $404.72 | |
| 93976 | <1% | 38 | $384.75 | |
| 82330 | <1% | 594 | $377.20 | |
| 70360 | <1% | 17 | $319.44 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 36 | $310.91 |
| 87045 | <1% | 198 | $297.26 | |
| 87507 | <1% | 14 | $278.36 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 313 | $272.81 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 313 | $216.48 |
| 76870 | <1% | 13 | $199.96 | |
| 82607 | <1% | 660 | $195.86 | |
| 82140 | <1% | 1,027 | $188.84 | |
| 84703 | <1% | 1,798 | $161.61 | |
| 84100 | <1% | 1,868 | $147.85 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,811 | $138.10 |
| 77080 | <1% | 14 | $127.73 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 24 | $125.70 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 121 | $123.71 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 349 | $114.42 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 145 | $103.81 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 14 | $85.29 |
| 84439 | <1% | 522 | $83.43 | |
| 87209 | <1% | 18 | $51.48 | |
| 82746 | <1% | 489 | $47.24 | |
| 82077 | <1% | 1,529 | $47.23 | |
| 87806 | <1% | 86 | $41.67 | |
| 85045 | <1% | 309 | $38.27 | |
| 80143 | <1% | 776 | $35.71 | |
| 80179 | <1% | 720 | $28.13 | |
| 88304 | <1% | 215 | $22.64 | |
| 82553 | <1% | 28 | $9.37 | |
| 87075 | <1% | 41 | $4.32 | |
| 86803 | <1% | 32 | $2.88 | |
| 80074 | <1% | 47 | $2.67 | |
| 87425 | <1% | 17 | $2.07 | |
| 87177 | <1% | 17 | $2.07 | |
| 87340 | <1% | 16 | $0.69 | |
| 71101 | <1% | 16 | $0.69 | |
| 99406 | 0% | 329 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 92 | $0.00 |
| 36430 | 0% | 14 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 702 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 43 | $0.00 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 0% | 38 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 18 | $0.00 |
| 82784 | 0% | 12 | $0.00 | |
| 86308 | 0% | 38 | $0.00 | |
| 86592 | 0% | 25 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 21 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 25 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 18 | $0.00 |
| 29105 | 0% | 14 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 14 | $0.00 |
| 82010 | 0% | 31 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 52 | $0.00 |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 0% | 17 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 15 | $0.00 |
| 82248 | 0% | 31 | $0.00 | |
| 90715 | 0% | 54 | $0.00 | |
| 29125 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPELL, KENNETH (CHIEF EXECUTIVE OFFICER)